Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANVS NASDAQ:SCLX NASDAQ:TPST NASDAQ:XLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$1.71+0.9%$1.84$1.54▼$5.50$58.55M1.19804,038 shs567,884 shsSCLXScilex$6.56-3.8%$7.64$4.20▼$34.27$57.91M1.66208,151 shs100,554 shsTPSTTempest Therapeutics$0.89+2.5%$1.20$0.84▼$12.23$13.92M-1.73181,099 shs157,293 shsXLOXilio Therapeutics$9.10-0.5%$8.70$6.47▼$12.74$60.16M-0.1449,576 shs12,139 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio+0.65%-2.18%-8.23%-13.67%-35.81%SCLXScilex-3.81%-6.69%-15.90%-37.64%-58.87%TPSTTempest Therapeutics+2.46%-6.17%-18.87%-55.16%-87.71%XLOXilio Therapeutics-0.55%+7.31%-1.83%+14.90%-7.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$1.71+0.9%$1.84$1.54▼$5.50$58.55M1.19804,038 shs567,884 shsSCLXScilex$6.56-3.8%$7.64$4.20▼$34.27$57.91M1.66208,151 shs100,554 shsTPSTTempest Therapeutics$0.89+2.5%$1.20$0.84▼$12.23$13.92M-1.73181,099 shs157,293 shsXLOXilio Therapeutics$9.10-0.5%$8.70$6.47▼$12.74$60.16M-0.1449,576 shs12,139 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio+0.65%-2.18%-8.23%-13.67%-35.81%SCLXScilex-3.81%-6.69%-15.90%-37.64%-58.87%TPSTTempest Therapeutics+2.46%-6.17%-18.87%-55.16%-87.71%XLOXilio Therapeutics-0.55%+7.31%-1.83%+14.90%-7.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANVSAnnovis Bio 2.60Moderate Buy$11.67584.26% UpsideSCLXScilex 1.00SellN/AN/ATPSTTempest Therapeutics 1.50ReduceN/AN/AXLOXilio Therapeutics 2.50Moderate Buy$28.00207.69% UpsideCurrent Analyst Ratings BreakdownLatest TPST, SCLX, ANVS, and XLO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026XLOXilio Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/13/2026TPSTTempest Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/9/2026ANVSAnnovis Bio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold7/7/2026ANVSAnnovis Bio Roth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.007/7/2026ANVSAnnovis Bio Roth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/6/2026ANVSAnnovis Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/1/2026XLOXilio Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/16/2026SCLXScilex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/15/2026XLOXilio Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/26/2026XLOXilio Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026TPSTTempest Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 7/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANVSAnnovis BioN/AN/AN/AN/A$0.64 per shareN/ASCLXScilex$30.25M1.84N/AN/A($24.94) per share-0.26TPSTTempest TherapeuticsN/AN/AN/AN/A$1.35 per shareN/AXLOXilio Therapeutics$43.77M1.37N/AN/A$7.31 per share1.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANVSAnnovis Bio-$28.85M-$1.71N/AN/AN/AN/A-318.08%-215.47%8/11/2026 (Estimated)SCLXScilex-$358.73M-$40.47N/AN/AN/A-1,110.17%N/A-143.55%9/2/2026 (Estimated)TPSTTempest Therapeutics-$26.26M-$6.01N/AN/AN/AN/A-355.61%-121.21%8/10/2026 (Estimated)XLOXilio Therapeutics-$35.04M-$3.55N/AN/AN/A-58.52%-151.42%-27.61%8/13/2026 (Estimated)Latest TPST, SCLX, ANVS, and XLO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026XLOXilio Therapeutics-$0.59N/AN/AN/A$12.72 millionN/A8/11/2026Q2 2026ANVSAnnovis Bio-$0.44N/AN/AN/AN/AN/A8/10/2026Q2 2026TPSTTempest Therapeutics-$0.30N/AN/AN/AN/AN/A5/20/2026Q1 2026SCLXScilex-$0.3373-$4.76-$4.4227-$6.28$15.00 million$8.61 million5/15/2026Q1 2026ANVSAnnovis Bio-$0.3950-$0.63-$0.2350-$0.63N/AN/A5/14/2026Q1 2026TPSTTempest Therapeutics-$0.28-$2.53-$2.25-$2.53N/AN/A5/12/2026Q1 2026XLOXilio Therapeutics-$0.66-$0.58+$0.08-$0.58$8.52 million$12.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANVSAnnovis BioN/AN/AN/AN/AN/ASCLXScilexN/AN/AN/AN/AN/ATPSTTempest TherapeuticsN/AN/AN/AN/AN/AXLOXilio TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANVSAnnovis BioN/A1.271.27SCLXScilexN/A0.080.07TPSTTempest TherapeuticsN/A0.740.74XLOXilio TherapeuticsN/A3.593.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANVSAnnovis Bio15.83%SCLXScilex69.67%TPSTTempest Therapeutics22.52%XLOXilio Therapeutics54.29%Insider OwnershipCompanyInsider OwnershipANVSAnnovis Bio20.80%SCLXScilex4.50%TPSTTempest Therapeutics36.20%XLOXilio Therapeutics7.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANVSAnnovis Bio334.65 million27.44 millionOptionableSCLXScilex808.49 million8.11 millionNo DataTPSTTempest Therapeutics2015.98 million10.20 millionNo DataXLOXilio Therapeutics706.58 million6.09 millionNot OptionableTPST, SCLX, ANVS, and XLO HeadlinesRecent News About These CompaniesXilio Therapeutics (NASDAQ:XLO) Shares Down 0.3% - Time to Sell?July 9, 2026 | marketbeat.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 6, 2026 | markets.businessinsider.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 6, 2026 | globenewswire.comXilio Therapeutics, Inc.: Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal OfficerJune 29, 2026 | finanznachrichten.deXilio Therapeutics Appoints Ben Harshbarger as Chief Legal OfficerJune 29, 2026 | globenewswire.comXilio Therapeutics IncJune 2, 2026 | edition.cnn.comCancer Stocks That Are Advancing the Future of Oncology CareMay 18, 2026 | zacks.comXilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue EstimatesMay 12, 2026 | zacks.comXilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business UpdatesMay 12, 2026 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7, 2026 | globenewswire.comXilio Therapeutics (XLO) price target decreased by 28.57% to 20.40April 28, 2026 | msn.comXilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2April 17, 2026 | globenewswire.comXilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of DirectorsApril 16, 2026 | markets.businessinsider.comXilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.April 16, 2026 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 3, 2026 | globenewswire.comXilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?April 1, 2026 | zacks.comXilio Therapeutics (XLO) price target increased by 1,300.00% to 28.56March 28, 2026 | msn.comCancer Stocks to Buy as Innovation Reshapes Global Oncology MarketMarch 26, 2026 | zacks.comXilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial ResultsMarch 23, 2026 | globenewswire.comXilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual MeetingMarch 17, 2026 | globenewswire.comXilio Therapeutics Announces 1-for-14 Reverse Stock SplitMarch 12, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTPST, SCLX, ANVS, and XLO Company DescriptionsAnnovis Bio NYSE:ANVS$1.70 +0.02 (+0.89%) Closing price 07/29/2026 03:59 PM EasternExtended Trading$1.70 0.00 (0.00%) As of 07/29/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Scilex NASDAQ:SCLX$6.56 -0.26 (-3.81%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$6.70 +0.15 (+2.21%) As of 07/29/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.Tempest Therapeutics NASDAQ:TPST$0.89 +0.02 (+2.46%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$0.87 -0.02 (-2.51%) As of 06:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.Xilio Therapeutics NASDAQ:XLO$9.10 -0.05 (-0.55%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$8.92 -0.18 (-1.98%) As of 07/29/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why SK hynix Could Be the Best AI Chip Stock to Buy Now Why Bloom Energy May Be the Most Important AI Infrastructure Stock Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead? Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters Broadcom’s $200 Billion Samsung Deal Shows How Costly the AI Memory Race Has Become Meta’s AI Spending Problem Just Found a BlackRock Solution Carrier Earnings Could Send the Stock to a New All-Time High Amazon’s Satellite Push Raises the Stakes for SpaceX and AST SpaceMobile Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
